Analysis: Charles River Laboratories International, Inc.
US:CRL
Why is Charles River Laboratories International, Inc. stock rising?
Charles River raised its FY2026 organic revenue guidance to flat-to-1% growth.
New collaboration with Eli Lilly's TuneLab platform will use Charles River's wet-lab testing expertise to support Lilly's AI and machine learning drug discovery model.
New collaboration with Arovella Therapeutics will provide next-generation sequencing services for cell and gene therapy cancer programs.
Charles River is rolling out an AI-enabled digital pathology workflow intended to reduce standard pathology timelines for clients.
Charles River is expanding bioanalytical laboratory capacity at Heriot Watt University's Research Park in Scotland, with benefits expected beyond 2026.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Charles River Laboratories International, Inc. and 4,900+ companies.